JAK1 (Ab-1022) Antibody

What is JAK1 (Ab-1022) Antibody and what epitope does it recognize?

JAK1 (Ab-1022) Antibody is a rabbit polyclonal antibody that specifically detects endogenous levels of total JAK1 protein. The antibody recognizes a peptide sequence around amino acids 1020-1024 (K-E-Y-Y-T) derived from Human JAK1 . This region is highly conserved across species, which accounts for the antibody's cross-reactivity with mouse and rat JAK1 proteins. The antibody is produced by immunizing rabbits with a synthetic peptide-KLH conjugate and subsequently purified by affinity chromatography using epitope-specific peptide columns . Unlike phospho-specific JAK1 antibodies that only detect activated forms, this antibody recognizes JAK1 regardless of its phosphorylation status, making it ideal for total JAK1 protein detection.

What are the validated applications for JAK1 (Ab-1022) Antibody?

The JAK1 (Ab-1022) Antibody has been validated for multiple experimental applications that are critical for JAK1 research:

The antibody has been specifically validated using multiple cell lines including 3T3, HepG2, HT29, and MDA cells, confirming its specificity and utility across different experimental contexts . For Western blotting applications, the antibody typically detects a band of approximately 130 kDa corresponding to JAK1 protein. When designing experiments, researchers should include appropriate positive controls, such as lysates from cells known to express JAK1, and negative controls to ensure specificity of detection.

What are the optimal storage and handling conditions for maintaining JAK1 (Ab-1022) Antibody activity?

To maintain optimal activity of JAK1 (Ab-1022) Antibody, follow these evidence-based storage and handling protocols:

For long-term preservation, store the antibody at -20°C in the provided formulation containing 50% glycerol . This prevents freeze-thaw damage to the antibody structure. For short-term use (within 1-2 weeks), the antibody can be stored at 4°C . The antibody is supplied at a concentration of 1.0 mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, containing 150 mM NaCl, 0.02% sodium azide, and 50% glycerol as stabilizers .

When working with the antibody, minimize exposure to room temperature and avoid repeated freeze-thaw cycles, as these can lead to protein denaturation and loss of binding activity. If frequent use is anticipated, consider preparing small working aliquots of the antibody to minimize freeze-thaw cycles. After each use, return the antibody promptly to the appropriate storage temperature. Additionally, avoid exposure to strong light, especially for conjugated antibodies, as this can lead to photobleaching of fluorophores.

How should JAK1 (Ab-1022) Antibody be optimized for Western blotting experiments?

Optimizing JAK1 (Ab-1022) Antibody for Western blotting requires careful consideration of several technical parameters:

• Sample Preparation: For complete extraction of JAK1 protein, use RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors (if phosphorylation studies are involved). For cell lines like Jurkat, K562, or 3T3, a protein concentration of 20-50 μg per lane typically yields detectable signals .

• Blocking Conditions: To minimize background, block membranes with 5% non-fat dry milk or 3-5% BSA in TBST for 1 hour at room temperature. For phospho-specific detection, BSA is preferred over milk as milk contains phosphoproteins that may interfere with detection.

• Antibody Dilution: Start with a 1:1000 dilution in blocking buffer and adjust based on signal intensity. Incubate membranes with primary antibody solution overnight at 4°C with gentle rocking for optimal binding.

• Washing Steps: Implement stringent washing with TBST (4-5 washes, 5 minutes each) to reduce background and non-specific binding.

• Detection Methods: For enhanced sensitivity, especially when detecting low abundance JAK1 in certain tissues, use chemiluminescent substrates with extended exposure times or consider signal amplification methods.

Validation data shows successful detection of JAK1 in multiple cell lines including 3T3, HepG2, HT29, and MDA cells using this optimization approach . When troubleshooting, adjust antibody concentration, incubation time, and washing stringency to achieve optimal signal-to-noise ratio.

How can JAK1 (Ab-1022) Antibody be used in conjunction with phospho-specific JAK1 antibodies to study JAK-STAT signaling dynamics?

Combining JAK1 (Ab-1022) Antibody with phospho-specific JAK1 antibodies enables comprehensive analysis of JAK-STAT signaling dynamics through a dual-detection approach:

To effectively study JAK1 activation in JAK-STAT pathways, researchers can implement a sequential or parallel detection strategy. In the sequential approach, perform Western blotting first with phospho-specific JAK1 antibodies (e.g., those targeting pTyr1022/pTyr1023) to detect activated JAK1, then strip and reprobe the membrane with JAK1 (Ab-1022) Antibody to detect total JAK1 levels. This allows calculation of the phosphorylated-to-total JAK1 ratio, which provides a normalized measure of JAK1 activation independent of variations in total protein expression.

For immunofluorescence studies, use different fluorophore-conjugated secondary antibodies for simultaneous detection of total and phosphorylated JAK1. Custom conjugation services offer multiple fluorophore options for this antibody, including AF488, AF555, AF594, and AF647 , allowing flexible experimental design and multicolor imaging.

When designing time-course experiments to monitor signaling dynamics, collect samples at strategically selected timepoints (e.g., 0, 5, 15, 30, 60 minutes post-stimulation) and process them in parallel to capture the transient nature of JAK1 phosphorylation. This approach has proven effective in elucidating cytokine receptor signaling mechanisms and can reveal important temporal aspects of JAK1 activation in response to various stimuli.

What are the critical considerations when using JAK1 (Ab-1022) Antibody in immunohistochemistry applications?

When employing JAK1 (Ab-1022) Antibody for immunohistochemistry, researchers must address several critical factors to ensure reliable and interpretable results:

• Fixation Method: Formalin-fixed, paraffin-embedded (FFPE) tissues require optimized antigen retrieval methods, typically heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0). Perform comparative testing to determine which method best preserves the JAK1 epitope recognized by this antibody.

• Blocking Endogenous Peroxidase and Biotin: For DAB-based detection systems, quench endogenous peroxidase activity with 3% hydrogen peroxide in methanol for 10-15 minutes before antibody incubation. If using avidin-biotin detection systems, block endogenous biotin with commercial biotin-blocking kits.

• Antibody Concentration and Incubation: Start with a 1:100 dilution and optimize based on tissue type and fixation method. For FFPE tissues, extended incubation periods (overnight at 4°C) often yield better results than shorter incubations at higher temperatures.

• Detection System Selection: For tissues with low JAK1 expression, employ amplification systems such as polymer-based detection methods or tyramide signal amplification to enhance sensitivity while maintaining specificity.

• Control Tissues: Include positive control tissues known to express JAK1 (e.g., lymphoid tissues, specific cancer cell lines) and negative controls (primary antibody omitted) in each staining run to validate staining specificity.

• Counterstaining Optimization: Adjust hematoxylin counterstaining intensity to facilitate clear visualization of JAK1 localization without obscuring specific antibody staining.

These methodological considerations are essential for distinguishing true JAK1 expression patterns from artifacts, particularly in complex tissue architectures where JAK1 may show cell type-specific or subcellular localization patterns.

How can researchers verify the specificity of JAK1 (Ab-1022) Antibody and troubleshoot nonspecific binding issues?

Verifying antibody specificity is critical for generating reliable research data. For JAK1 (Ab-1022) Antibody, implement these validation and troubleshooting strategies:

Validation Approaches:

• Peptide Competition Assay: Pre-incubate the antibody with excess immunizing peptide (sequence around aa. 1020~1024 of JAK1) before application to samples. Specific signals should be substantially reduced or eliminated.

• Knockout/Knockdown Controls: Use CRISPR/Cas9-mediated JAK1 knockout cell lines or siRNA-mediated JAK1 knockdown samples as negative controls. The specific band or staining should be absent or significantly reduced in these samples.

• Antibody Cross-Validation: Compare results with another validated anti-JAK1 antibody targeting a different epitope. Concordant results from antibodies recognizing distinct regions of JAK1 provide strong evidence of specificity.

Troubleshooting Nonspecific Binding:

• Optimize Blocking Conditions: If high background is observed, increase blocking agent concentration (5-10% BSA or non-fat dry milk) and extend blocking time to 2 hours at room temperature.

• Adjust Antibody Concentration: Titrate the antibody to determine the optimal concentration that maintains specific signal while minimizing background. Start with a series of dilutions (1:500, 1:1000, 1:2000, 1:5000) in Western blotting applications.

• Modify Washing Procedures: Increase the number and duration of washing steps with higher stringency buffers (e.g., TBST with 0.1-0.3% Tween-20) to reduce non-specific binding.

• Buffer Optimization: Test different blocking buffers (milk vs. BSA) and antibody diluents to identify conditions that minimize cross-reactivity with your specific sample type.

When persistent non-specific binding occurs, consider the nature of the bands or staining pattern – consistent background patterns may indicate cross-reactivity with structurally similar proteins, which can sometimes be resolved by using more stringent washing conditions or different blocking reagents.

What are the common pitfalls when detecting low-abundance JAK1 in primary cells or tissue samples, and how can they be addressed?

Detecting low-abundance JAK1 in primary cells or tissue samples presents several challenges that can be addressed through methodological refinements:

Common Pitfalls and Solutions:

• Insufficient Protein Extraction:

  • Pitfall: Standard lysis buffers may inadequately extract JAK1 from certain tissues.

  • Solution: Use specialized extraction buffers containing higher detergent concentrations (e.g., RIPA buffer supplemented with 1% SDS) and mechanical disruption methods for tough tissues. For muscle or brain tissues, consider specialized extraction protocols with tissue-specific modifications.

• Signal Sensitivity Limitations:

  • Pitfall: Standard detection methods may be insufficient for visualizing low JAK1 levels.

  • Solution: Implement signal amplification techniques such as tyramide signal amplification (TSA) for IHC or highly sensitive ECL substrates for Western blotting. Consider concentrating proteins through immunoprecipitation before Western blotting when dealing with very low abundance samples.

• High Background-to-Signal Ratio:

  • Pitfall: Weak specific signals are often obscured by background noise.

  • Solution: Extend antibody incubation times (overnight at 4°C) at higher dilutions (1:2000-1:5000) to favor high-affinity specific binding while reducing low-affinity non-specific interactions. Increase washing duration and stringency.

• Sample Degradation:

  • Pitfall: JAK1 degradation during sample processing leads to false negative results.

  • Solution: Add protease inhibitor cocktails immediately during sample collection and maintain samples at 4°C throughout processing. For tissues with high protease activity (like pancreas), consider specialized protease inhibitor formulations.

• Epitope Masking in Fixed Tissues:

  • Pitfall: Formalin fixation can mask the JAK1 epitope recognized by this antibody.

  • Solution: Optimize antigen retrieval methods by testing multiple approaches (heat-induced vs. enzymatic) and buffers (citrate pH 6.0 vs. EDTA pH 9.0) to maximize epitope exposure without causing tissue degradation.

By implementing these methodological refinements, researchers can enhance detection sensitivity while maintaining specificity, enabling meaningful analysis of JAK1 expression patterns even in challenging sample types with naturally low JAK1 abundance.

How can JAK1 (Ab-1022) Antibody be incorporated into multiplexed detection systems for comprehensive signaling pathway analysis?

JAK1 (Ab-1022) Antibody can be strategically incorporated into multiplexed detection systems using several advanced methodological approaches:

Fluorescence Multiplexing Strategies:
The antibody can be custom-conjugated to various fluorophores including AF488, AF555, AF594, AF647, and many others as listed in the available conjugation services . This flexibility enables multicolor immunofluorescence experiments where JAK1 detection can be combined with other pathway components. When designing 3-5 color panels, select fluorophores with minimal spectral overlap (e.g., AF488, AF555, AF647) and include appropriate single-color controls for spectral compensation.

Sequential Multiplexed Western Blotting:
For comprehensive signaling pathway analysis on the same membrane, implement a sequential stripping and reprobing strategy:

• Begin with detection of phosphorylated proteins (e.g., p-JAK1, p-STAT3)

• Document results carefully

• Strip the membrane (validate stripping efficiency)

• Reprobe with JAK1 (Ab-1022) Antibody

• Continue with additional pathway components (STAT3, SOCS proteins)

This approach allows correlation between JAK1 expression and activation of downstream effectors within the same sample.

Mass Cytometry (CyTOF) Applications:
For single-cell signaling analysis, the antibody can be metal-tagged for use in mass cytometry, allowing simultaneous detection of 30+ parameters. When designing such panels, include JAK1 (Ab-1022) Antibody alongside markers for cell identity, phospho-proteins (p-STAT1, p-STAT3, p-STAT5), and functional readouts to generate comprehensive signaling profiles at single-cell resolution.

Spatial Transcriptomics Integration:
Combine JAK1 immunodetection with spatial transcriptomics by performing immunofluorescence with JAK1 (Ab-1022) Antibody followed by in situ hybridization for JAK-STAT pathway transcripts. This approach reveals relationships between protein expression, activation state, and downstream transcriptional responses with spatial context.

When implementing these multiplexed approaches, careful optimization of each antibody in the panel is essential, particularly regarding concentration, incubation conditions, and potential cross-reactivity issues.

What considerations should researchers make when using JAK1 (Ab-1022) Antibody in conjunction with JAK inhibitors for functional studies?

When combining JAK1 (Ab-1022) Antibody with JAK inhibitors in experimental systems, researchers should consider several methodological aspects to ensure meaningful interpretation of results:

Experimental Design Considerations:

• Inhibitor Specificity Assessment:
  Most commercially available JAK inhibitors show varying degrees of specificity across JAK family members (JAK1, JAK2, JAK3, TYK2). When interpreting results, consider the selectivity profile of your chosen inhibitor. For example, tofacitinib has higher potency against JAK1 and JAK3 compared to JAK2, while baricitinib has greater selectivity for JAK1 and JAK2.

• Concentration-Response Relationships:
  Establish dose-response curves for your specific cellular system rather than relying solely on published IC50 values. Using JAK1 (Ab-1022) Antibody alongside phospho-specific JAK1 antibodies allows quantification of inhibitor effects on both JAK1 expression and activation status across a range of concentrations.

• Temporal Dynamics:
  Design time-course experiments to distinguish between immediate signaling inhibition and secondary adaptive responses. JAK inhibitors may induce feedback mechanisms that alter JAK1 expression levels over time, which can be monitored using the JAK1 (Ab-1022) Antibody.

• Pathway Crosstalk Monitoring:
  JAK inhibition may affect multiple downstream pathways beyond STAT signaling. Consider using JAK1 (Ab-1022) Antibody in combination with antibodies against MAP kinase, PI3K/AKT, and other potential crosstalk pathways to comprehensively assess inhibitor effects.

• Control Selection:
  Include both vehicle controls and inactive structural analogs of your JAK inhibitor when possible. Additionally, consider genetic controls (JAK1 knockdown/knockout) to distinguish between on-target and off-target inhibitor effects.

• Washout Studies:
  To distinguish between reversible signaling inhibition and irreversible cellular changes, design washout experiments where inhibitors are removed after defined treatment periods, followed by analysis of JAK1 expression and phosphorylation recovery using appropriate antibodies.

By carefully addressing these considerations, researchers can generate more robust and interpretable data on JAK inhibitor mechanisms and efficacy, while avoiding common pitfalls in experimental design and interpretation.

How does JAK1 (Ab-1022) Antibody performance compare with other JAK1 detection antibodies across different experimental platforms?

Comparative analysis of JAK1 (Ab-1022) Antibody with other commercially available JAK1 antibodies reveals important performance differences across experimental platforms:

Western Blotting Performance Comparison:

The JAK1 (Ab-1022) Antibody shows particularly strong performance in Western blotting applications with validated detection in multiple cell lines including 3T3, HepG2, HT29, and MDA cells . Its polyclonal nature provides robust detection across species (human, mouse, rat) due to recognition of a conserved epitope.

Immunohistochemistry/Immunofluorescence Considerations:
In tissue applications, JAK1 (Ab-1022) Antibody typically requires more optimization than monoclonal alternatives but offers advantages in detecting JAK1 across different conformational states. The polyclonal nature of this antibody makes it potentially more resistant to epitope masking caused by fixation procedures, though this advantage must be balanced against potentially higher background than monoclonal alternatives.

Flow Cytometry Applications:
While not specifically validated for flow cytometry in the provided information, polyclonal antibodies like JAK1 (Ab-1022) generally require more extensive blocking and washing steps to achieve acceptable signal-to-noise ratios in flow cytometry compared to monoclonals. If flow cytometry applications are planned, custom conjugation to appropriate fluorophores followed by careful titration is recommended.

Selection Guidance:
When selecting between JAK1 (Ab-1022) Antibody and alternatives, consider:

• Experimental application (WB vs. IHC vs. IP)

• Need for species cross-reactivity (this antibody works across human, mouse, rat)

• Requirement for total JAK1 detection vs. phospho-specific detection

• Sample type and preparation method

This comparative analysis provides a framework for selecting the most appropriate JAK1 antibody based on specific experimental requirements and platform considerations.

What methodological approaches can researchers employ to study JAK1 expression and phosphorylation in the context of cytokine receptor signaling using JAK1 (Ab-1022) Antibody?

To effectively study JAK1 in cytokine receptor signaling contexts, researchers can implement several sophisticated methodological approaches using JAK1 (Ab-1022) Antibody:

Temporal Signaling Dynamics Analysis:

• Pulse-Chase Stimulation: Treat cells with relevant cytokines (IL-6, IFNs, IL-2 family cytokines) for precise time intervals (0-120 minutes).

• Sequential Extraction: Prepare cellular fractions (cytosolic, membrane, nuclear) to track JAK1 translocation during signaling.

• Dual Detection: Process parallel samples for both total JAK1 (using Ab-1022) and phosphorylated JAK1 (using phospho-specific antibodies) to calculate activation ratios independent of expression changes.

Receptor Complex Co-Immunoprecipitation:

• Receptor Pulldown: Immunoprecipitate specific cytokine receptors (e.g., IL-6R, IFNAR, IL-2R) followed by JAK1 detection using JAK1 (Ab-1022) Antibody.

• Reverse Approach: Use JAK1 immunoprecipitation followed by receptor detection to identify receptor associations.

• Complex Composition Analysis: Combine with detection of other JAKs (JAK2, JAK3, TYK2) to determine receptor-specific JAK utilization patterns.

Proximity-Based Interaction Studies:

• Proximity Ligation Assay (PLA): Combine JAK1 (Ab-1022) Antibody with antibodies against cytokine receptors or STAT proteins to visualize molecular proximities (<40 nm) as fluorescent spots.

• FRET/BRET Analysis: If using tagged proteins, complement with JAK1 antibody detection to validate expression levels of fusion proteins.

Pharmacological Intervention Approaches:

• Inhibitor Specificity Testing: Compare effects of JAK1-selective vs. pan-JAK inhibitors on JAK1 phosphorylation and complex formation.

• Recovery Kinetics: After inhibitor washout, monitor JAK1 re-activation rates across different receptor systems.

• Differential Pathway Inhibition: Combine with inhibitors of parallel pathways (MAPK, PI3K) to identify signaling crosstalk points.

Single-Cell Analysis Methods:

• Imaging Flow Cytometry: Combine JAK1 and phospho-JAK1 detection with receptor localization at single-cell resolution.

• Cell Population Heterogeneity: Use JAK1 (Ab-1022) Antibody in flow cytometry (after custom conjugation) to correlate JAK1 expression with activation markers across heterogeneous populations.

Each of these methodologies provides unique insights into JAK1 biology in cytokine signaling contexts, from molecular associations to spatiotemporal dynamics, allowing researchers to address sophisticated questions about signal integration and pathway specificity.

How might JAK1 (Ab-1022) Antibody be utilized in emerging research areas such as single-cell analysis and spatial proteomics?

JAK1 (Ab-1022) Antibody has significant potential applications in cutting-edge research methodologies that provide unprecedented resolution of JAK1 biology:

Single-Cell Proteomic Applications:
The antibody can be incorporated into mass cytometry (CyTOF) panels after metal conjugation, enabling simultaneous measurement of JAK1 expression alongside dozens of other proteins at single-cell resolution. This approach could reveal previously unrecognized cellular subpopulations with distinct JAK1 expression levels in heterogeneous samples like tumor biopsies or immune cell infiltrates. The ability to custom conjugate this antibody to various fluorophores also facilitates its integration into spectral flow cytometry panels for high-dimensional analysis of JAK1 in relation to cellular phenotypes.

Spatial Proteomics Approaches:
In the rapidly evolving field of spatial proteomics, JAK1 (Ab-1022) Antibody can be employed in:

• Multiplexed Ion Beam Imaging (MIBI): After metal conjugation, the antibody can be used to visualize JAK1 distribution across tissue architectures with subcellular resolution while preserving spatial relationships.

• Cyclic Immunofluorescence (CycIF): The antibody can be incorporated into sequential staining/quenching cycles, enabling co-detection of JAK1 with 30+ other proteins on the same tissue section to map signaling networks in their native spatial context.

• Digital Spatial Profiling (DSP): When coupled with appropriate barcodes, the antibody could enable quantitative spatial analysis of JAK1 expression across designated regions of interest in complex tissues.

Emerging Microfluidic Applications:
JAK1 (Ab-1022) Antibody can be utilized in microfluidic-based single-cell secretion systems to correlate JAK1 expression or activation state with functional outputs like cytokine secretion at single-cell resolution. This approach could reveal how JAK1 signaling heterogeneity contributes to functional diversity within apparently homogeneous cell populations.

Integrative Multi-Omics:
The antibody can serve as a protein-level validation tool in multi-omics studies, confirming JAK1 protein expression patterns predicted from transcriptomic or epigenomic analyses. This integration is particularly valuable for understanding post-transcriptional regulation mechanisms affecting JAK1 protein levels independently of mRNA abundance.

These emerging applications represent the cutting edge of JAK1 research methodology, offering unprecedented insights into the spatial organization, cell-specific expression patterns, and functional heterogeneity of JAK1 in complex biological systems.

What are the potential applications of JAK1 (Ab-1022) Antibody in understanding therapeutic resistance mechanisms to JAK inhibitors in clinical settings?

JAK1 (Ab-1022) Antibody offers substantial potential for elucidating mechanisms of therapeutic resistance to JAK inhibitors in translational and clinical research contexts:

Resistance Biomarker Discovery:
By analyzing JAK1 expression levels using JAK1 (Ab-1022) Antibody in patient samples before treatment and at resistance development, researchers can determine whether altered JAK1 expression correlates with clinical outcomes. This approach can identify whether JAK1 upregulation represents a compensatory mechanism in response to chronic JAK inhibition. The antibody's ability to detect total JAK1 regardless of phosphorylation status makes it particularly valuable for distinguishing between resistance mechanisms involving altered protein expression versus modified activation patterns.

Mutation-Driven Resistance Characterization:
Combining JAK1 (Ab-1022) Antibody with sequencing approaches allows correlation between JAK1 mutations and protein expression/localization changes:

• Epitope Preservation Analysis: For tumors harboring JAK1 mutations, this antibody can help determine whether the protein remains expressed and correctly localized despite sequence alterations.

• Structural Consequence Assessment: By comparing JAK1 detection patterns between wildtype and mutant proteins, researchers can infer whether mutations affect protein stability, cellular localization, or interaction capabilities.

Adaptive Signaling Network Mapping:
JAK1 (Ab-1022) Antibody can be employed in multiplex immunofluorescence or mass cytometry panels to map adaptive signaling changes in resistant cells:

• Pathway Rewiring Detection: By simultaneously monitoring JAK1 and alternative signaling nodes (MAPK, PI3K/AKT) in resistant samples, researchers can identify compensatory pathway activation patterns.

• Spatial Signaling Organization: Using imaging approaches, the antibody can reveal whether JAK inhibitor resistance involves altered subcellular localization of JAK1 or changes in its co-localization with receptor complexes.

Therapeutic Resistance Monitoring in Clinical Samples:
The validated cross-reactivity of this antibody with human, mouse, and rat JAK1 makes it valuable for translational research spanning preclinical models to patient samples:

• Serial Biopsy Analysis: In clinical settings where sequential biopsies are available, the antibody can track JAK1 expression changes during treatment and at progression.

• Predictive Biomarker Development: By correlating baseline JAK1 expression patterns with subsequent clinical responses, researchers can evaluate whether JAK1 levels or localization patterns have predictive value for JAK inhibitor efficacy.

These applications highlight how JAK1 (Ab-1022) Antibody can contribute to understanding and potentially overcoming therapeutic resistance to JAK inhibitors, ultimately improving patient selection and treatment strategies in JAK1-dependent malignancies and inflammatory diseases.